StockData
BioAge Labs, Inc. logo

BioAge Labs, Inc. (BIOA) company profile

BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$5.10−0.12 (-2.30%)

Close on Nov 17, 2026Market cap $234.07MP/E –Yield –

About BioAge Labs

Pharmaceutical Preparations, SIC 2834

BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic candidates for chronic metabolic diseases by targeting human aging biology. The company leverages a proprietary computational platform built on longitudinal human datasets and biobanked samples to identify molecular drivers of longevity and healthspan. Its lead product candidate, BGE-102, is an orally administered, brain-penetrant small-molecule NLRP3 inhibitor under development for cardiometabolic indications, particularly cardiovascular risk reduction in patients with obesity, and ophthalmology indications including diabetic macular edema. BioAge is also advancing apelin receptor agonists for obesity as well as earlier-stage discovery programs in collaboration with major pharmaceutical partners.

The company operates primarily through research and clinical trial collaborations, partnering on discovery and pipeline programs with firms such as Eli Lilly and Company, Novartis Pharma AG, and JiKang Therapeutics. BioAge conducts its clinical activities in clinical trial units and maintains discovery collaborations with academic institutions such as the University of Bonn. The company is co-founded and led by an executive management team based in North America.

Summary of the business section of BioAge Labs's latest annual report, written by StockData.

Company profile

Company

Legal name
BioAge Labs, Inc.
Headquarters
Emeryville, CA
Address
5885 Hollis Street, Suite 370 94608
Phone
(510) 806-1445
Employees
62, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Francisco, California

Stock & identifiers

Ticker
BIOA
Exchange
Nasdaq
IPO date
Sep 26, 2024
Shares outstanding
46M, Jul 31, 2026
Public float
$112.70M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1709941
CUSIP
09077V100
ISIN
US09077V1008
FIGI
BBG00HBTB0M9
Share class FIGI
BBG00HBTB0N8
LEI
529900NG0C40250Z7875
EIN
47-4721157

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eric MorgenChief Operating Officer, Director67,225
Kristen FortneyChief Executive Officer, Director976,949
Shane BartonPrincipal Accounting Officer4,290
Dov A. Goldstein MdChief Financial Officer36,575
Paul D. RubinChief Medical Officer0
James HealyDirector2,304,901
Jean Pierre GarnierDirector–
Vijay Satyanand PandeDirector3,233,170
Patrick G. EnrightDirector1,710,589
Michael H. DavidsonDirector–
Rekha HemrajaniDirector3,000

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Kristen Fortney
Chief Executive Officer and President
$600.00K$1.94M$330.00K$15.20K$2.89M-76%
Eric Morgen
Chief Operating Officer
$499.60K$732.60K$199.84K$15.20K$1.45M-41%
Paul Rubin
Chief Medical Officer
$520.20K$732.60K$208.08K$15.20K$1.48M-23%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 26, 2024
Offer price
$18.00
Securities offered
11,000,000
Gross proceeds
$198.00M
Exchange
Nasdaq
First trading day
Sep 26, 2024
First-day close
$18.31+1.7%
Lock-up ends (est.)
Mar 25, 2025

“The initial public offering price is $18.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 62 employees, 60 of whom were full-time and 44 of whom were engaged in research and development activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?